Insider Selling: Oxford Immunotec Global PLC (OXFD) CEO Sells $149,100.00 in Stock

Share on StockTwits

Oxford Immunotec Global PLC (NASDAQ:OXFD) CEO Peter Wrighton-Smith sold 10,000 shares of the firm’s stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $14.91, for a total value of $149,100.00. Following the sale, the chief executive officer now directly owns 423,469 shares of the company’s stock, valued at approximately $6,313,922.79. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of Oxford Immunotec Global stock opened at $14.90 on Monday. Oxford Immunotec Global PLC has a 1 year low of $10.00 and a 1 year high of $19.19. The firm has a market cap of $387.25 million, a price-to-earnings ratio of -10.96 and a beta of 0.11.

Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Friday, November 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.14). Oxford Immunotec Global had a negative net margin of 12.51% and a negative return on equity of 41.15%. The business had revenue of $16.10 million for the quarter, compared to analyst estimates of $33.60 million. During the same period in the prior year, the business earned ($0.70) EPS. The company’s revenue for the quarter was up 7.3% compared to the same quarter last year. Equities research analysts expect that Oxford Immunotec Global PLC will post -1.09 earnings per share for the current fiscal year.

Several equities research analysts have issued reports on the company. Zacks Investment Research raised Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Thursday. BidaskClub raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine downgraded Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 1st. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Oxford Immunotec Global in a report on Sunday, November 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $16.67.

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc lifted its holdings in Oxford Immunotec Global by 2.0% during the 3rd quarter. Vanguard Group Inc now owns 95,647 shares of the company’s stock valued at $1,552,000 after purchasing an additional 1,839 shares during the last quarter. Wells Fargo & Company MN increased its position in Oxford Immunotec Global by 11.2% during the 3rd quarter. Wells Fargo & Company MN now owns 45,820 shares of the company’s stock worth $744,000 after buying an additional 4,605 shares during the period. Citadel Advisors LLC increased its position in Oxford Immunotec Global by 6.2% during the 3rd quarter. Citadel Advisors LLC now owns 84,689 shares of the company’s stock worth $1,375,000 after buying an additional 4,911 shares during the period. Northern Trust Corp increased its position in Oxford Immunotec Global by 3.1% during the 2nd quarter. Northern Trust Corp now owns 265,487 shares of the company’s stock worth $3,423,000 after buying an additional 7,862 shares during the period. Finally, Renaissance Technologies LLC increased its position in Oxford Immunotec Global by 84.7% during the 2nd quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock worth $271,000 after buying an additional 9,658 shares during the period. 90.94% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was posted by Fairfield Current and is the property of of Fairfield Current. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.fairfieldcurrent.com/news/2019/01/14/insider-selling-oxford-immunotec-global-plc-oxfd-ceo-sells-149100-00-in-stock.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Recommended Story: Earnings Reports

Insider Buying and Selling by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply